PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab -paclitaxel (FA) and nab -paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development. (2019)

First Author: Grose D

Attributed to: Exploring novel solutions of radiotherapy delivery and using biology, imaging, new fractionations and radiobiological models to improve TCP/NTCP ratio funded by MRC

No abstract provided

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 15_suppl